# Surgical Innovation Associates

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/surgical-innovation-associates

- Industry: Medical Devices & Equipment
- Headquarters: Chicago, US
- Website: www.sia.health
- Total disclosed funding: $4M
- Latest round: Series A (Oct 2, 2019)
- Investors on record: 2

## About

Surgical Innovation Associates, Inc. specializes in developing and providing innovative surgical products designed to enhance soft tissue support in surgical procedures, primarily focusing on the healthcare sector in the U.S. and Europe.Founded in 2014 by Alexei Mlodinow, Surgical Innovation Associates, Inc. is based in Chicago, US. The company has engaged in five deals with the most recent transaction occurring on December 1, 2022, involving a Trade Sale where Integra LifeSciences Holdings Corporation acquired the company for USD 50 mn. The acquisition aims to further Integra's global strategy in breast reconstruction, particularly in U.S. markets with FDA-approved devices for implant-based breast reconstruction procedures.Surgical Innovation Associates, Inc. offers DuraSorb® Monofilament Mesh, a fully-resorbable knitted mesh engineered to enhance soft tissue support in various surgical applications. It is marketed towards hospitals and surgical centers in the U.S. and Europe, catering to licensed medical professionals such as general surgeons and specialists focused on soft tissue repairs, ensuring compatibility with specific surgical instruments provided by the company.Revenue is generated through the sale of DuraSorb® Monofilament Mesh to healthcare facilities, structured as direct sales to hospitals and surgical centers. Pricing is determined by individual product specifications and may include bulk purchasing agreements, with a focus on meeting regulatory standards and addressing the needs of medical clientele.Following the recent acquisition by Integra LifeSciences Holdings Corporation, closing by the end of 2022, Surgical Innovation Associates, Inc. is set to advance its product offerings specifically in the implant-based breast reconstruction market. The acquisition will facilitate access to the U.S. market with devices approved by the FDA for breast reconstruction procedures. This strategic move is aimed at enhancing the company’s portfolio and expanding its reach in the surgical product landscape.

## Funding rounds

- Series A, Oct 2, 2019, $4M — Harvard Business School Alumni Angels, Gopher Angels

## Investors

- Harvard Business School Alumni Angels — Series A
- Gopher Angels (https://capitalatlas.ai/funds/gopher-angels) — Series A